close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SAB Biotherapeutics, Inc. - Common Stock (NQ:SABS)

3.960 +0.340 (+9.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SAB Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces Departure of Chief Financial Officer
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
SABS Stock Earnings: SAB Biotherapeutics Misses EPS for Q1 2024 ↗
SABS stock results show that SAB Biotherapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
This regulatory clearance enables clinical development of SAB-142 in patients with type 1 diabetes in the US 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Provides SAB-142 Trial Update
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics to Present at INNODIA Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces Executive Leadership Change
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Applied Therapeutics, Inc. 
Via Benzinga
News headline image
Cal-Maine Foods, UniFirst And 3 Stocks To Watch Heading Into Wednesday ↗
With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
News headline image
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
VerifyMe And 3 Other Stocks Under $2 Insiders Are Buying ↗
The Dow Jones closed higher by more than 500 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
News headline image
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: SAB Biotherapeutics Kickstarts Phase 1 Study For Its Lead Type 1 Diabetes Hopeful In Australia ↗
SAB Biotherapeutics Inc (NASDAQ: SABS) announced that the first HUMAN trial participants (Fully HUman anti-thymocyte biologic in a first-in-MAN clinical study) have been dosed in Australia.  
Via Benzinga
News headline image
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
Finance leader joins SAB with more than 25 years of experience as a leading biotech equity research analyst 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today